<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00220766</url>
  </required_header>
  <id_info>
    <org_study_id>100348</org_study_id>
    <nct_id>NCT00220766</nct_id>
  </id_info>
  <brief_title>Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients</brief_title>
  <official_title>IGIV-C 10% Rapid Infusion Trial in Primary Immune Deficient Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grifols Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grifols Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine if the safety and tolerability of Immune Globulin&#xD;
      Intravenous (Human), 10% caprylate/chromatography (IGIV-C)purified is similar when infused at&#xD;
      two different infusion rates. The primary objective is to compare the incidence and severity&#xD;
      of all infusion related adverse events when IGIV-C, 10% is administered at a rate of 0.14&#xD;
      mL/kg/min compared to a rate of 0.08 mL/kg/min after a single daily infusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single blind, randomized, multi-center cross-over trial in patients&#xD;
      with Primary Immune Deficiency. Patients with a confirmed diagnosis of primary Immune&#xD;
      Deficiency will be treated with two daily infusions given 3-4 weeks apart at the fixed&#xD;
      individual IGIV dose regimen (400-600 mg/kg) established prior to entry into the study. Any&#xD;
      subject with an established dose in the range of 200-399 mg/kg will be assigned to receive&#xD;
      400 mg/kg during the course of the study during the same dosing schedule established prior to&#xD;
      entry into the study.&#xD;
&#xD;
      After a screening period lasting not more than four weeks, patients will be randomized into&#xD;
      one of two cross-over groups. Patients randomized to Group 1 will receive their first IGIV-C,&#xD;
      10% dose at a rate of 0.08 mL/kg/min and their second infusion at a rate of 0.14 mL/kg/min,&#xD;
      whereas patients randomized to Group 2 will receive IGIV-C, 10% at a rate of 0.14 mL/kg/min&#xD;
      on the first infusion day and then 0.08 mL/kg/min on the second infusion day. All patients&#xD;
      just prior to each IGIV-C, 10% infusion will receive the same volume of 5% dextrose as&#xD;
      calculated for their IGIV-C, 10% infusion and given at a target rate according to the schema&#xD;
      below.&#xD;
&#xD;
      Group 1:&#xD;
&#xD;
        -  Infusion #1 (Week 0)Dextrose (0.14 mL/kg/min), then IGIV-C, 10% (0.08 mL/kg/min)&#xD;
&#xD;
        -  Infusion #2 (Week 3-4)Dextrose (0.08 mL/kg/min), then IGIV-C, 10% (0.14 mL/kg/min)&#xD;
&#xD;
      Group 2:&#xD;
&#xD;
        -  Infusion #1 (Week 0)Dextrose (0.08 mL/kg/min), then IGIV-C, 10% (0.14 mL/kg/min)&#xD;
&#xD;
        -  Infusion #2 Dextrose (0.14 mL/kg/min), then IGIV-C, 10% (0.08 mL/kg/min)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">March 2004</completion_date>
  <primary_completion_date type="Actual">August 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infusion related adverse events</measure>
    <time_frame>within 72 hours after infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All adverse events</measure>
    <time_frame>within 72 hours after infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Immunologic Deficiency Syndrome</condition>
  <condition>Agammaglobulinemia</condition>
  <condition>Severe Combined Immunodeficiency</condition>
  <condition>Wiskott-Aldrich Syndrome</condition>
  <condition>Common Variable Immunodeficiency</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion #1 (Week 0)Dextrose (0.14 mL/kg/min), then IGIV-C, 10% (0.08 mL/kg/min) ; Infusion #2 (Week 3-4)Dextrose (0.08 mL/kg/min), then IGIV-C, 10% (0.14 mL/kg/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion #1 (Week 0)Dextrose (0.08 mL/kg/min), then IGIV-C, 10% (0.14 mL/kg/min); Infusion #2 Dextrose (0.14 mL/kg/min), then IGIV-C, 10% (0.08 mL/kg/min)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Gamunex</other_name>
    <other_name>IGIVnex</other_name>
    <other_name>Gaminex</other_name>
    <other_name>IGIV-C</other_name>
    <other_name>Immune Globulin Intravenous (Human) , 10%</other_name>
    <other_name>IGIV</other_name>
    <other_name>BAY 41-1000</other_name>
    <other_name>TAL-05-00004</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextrose, 5% in Water</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of primary immune deficiency and medical records available for&#xD;
             retrospective review for at least 3 months prior to entry into the trial&#xD;
&#xD;
          -  Signed an informed consent written informed consent prior to initiation of any study&#xD;
             related procedures&#xD;
&#xD;
          -  Receiving regular infusions of IGIV at a fixed interval and dosage (in the range of&#xD;
             200-600 mg/kg given every 3-4 weeks) for at least three months prior to entry into the&#xD;
             trial. Patients who are currently receiving less than 400 mg/kg are eligible for this&#xD;
             trial and will be at the time of study enrollment be treated at 400 mg/kg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or suspicion of significant allergic reaction to intravenous immune globulin,&#xD;
             and/or blood products&#xD;
&#xD;
          -  Documented history of selective IgA deficiency (serum level &lt;5.0 mg/dL) and known&#xD;
             antibodies to IgA&#xD;
&#xD;
          -  Isolated IgG subclass deficiency with a normal total serum IgG level&#xD;
&#xD;
          -  Other conditions which may interfere with the trial, include the patients demeanor or&#xD;
             mental ability to follow instruction.&#xD;
&#xD;
          -  Pretreatment with anti-pyretics or anti-histamines&#xD;
&#xD;
          -  Congestive heart failure (New York Heart Association stage greater than Class II)&#xD;
&#xD;
          -  Renal insufficiency (creatinine &gt;2.5 mg/dL)&#xD;
&#xD;
          -  Conditions whose symptoms and effects could alter protein catabolism and/or IgG&#xD;
             utilization (e.g. protein-losing enteropathies, nephrotic syndrome)&#xD;
&#xD;
          -  Pretreatment routinely required to control/ameliorate IGIV infusion-related adverse&#xD;
             events (AEs)&#xD;
&#xD;
          -  Any patient who requires IGIV dosing more frequently than every 3 weeks to maintain&#xD;
             adequate trough levels&#xD;
&#xD;
          -  Women of child bearing potential who do not practice adequate contraception (i.e.&#xD;
             chemical or mechanical methods) and pregnant or lactating females&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erwin Gelfand, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Medical and Research Center, Denver, CO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Departments of Medicine and Microbiology</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Medical and Researach Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Center for Interdisciplinary Studies of Immunology</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Associates of the Palm Beaches</name>
      <address>
        <city>North Palm Beach</city>
        <state>Florida</state>
        <zip>33408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida College of Medicine</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clinical Trials Center, Children's Hospital</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy, Asthma, and Immunology</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimed Research, LLC</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3031 Hospital Drive Northwest</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4V 1R2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>September 24, 2009</last_update_submitted>
  <last_update_submitted_qc>September 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Gerald Klein, MD, Chief Medical Officer, Vice President of Medical and Clinical Affairs</name_title>
    <organization>Talecris Biotherapeutics, Inc.</organization>
  </responsible_party>
  <keyword>Primary Immune Deficiency</keyword>
  <keyword>IGIV</keyword>
  <keyword>Immunoglobulin G</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wiskott-Aldrich Syndrome</mesh_term>
    <mesh_term>Agammaglobulinemia</mesh_term>
    <mesh_term>Severe Combined Immunodeficiency</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Common Variable Immunodeficiency</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

